{"id":"low-dose-tamoxifen","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal discharge or bleeding"},{"rate":null,"effect":"Thromboembolic events"},{"rate":null,"effect":"Endometrial hyperplasia or cancer"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamoxifen is a nonsteroidal antiestrogen that competitively binds to estrogen receptors, preventing estrogen-mediated proliferation in hormone-responsive breast cancer cells. At low doses, it may also exert immunomodulatory effects that enhance immune function, potentially useful in conditions beyond traditional hormone-responsive breast cancer.","oneSentence":"Low-dose tamoxifen acts as a selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while potentially having immunomodulatory effects at reduced doses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:36.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (investigational low-dose formulation)"},{"name":"Potential immunomodulatory applications (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT05941520","phase":"PHASE2","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-23","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":80},{"nctId":"NCT06195306","phase":"PHASE2","title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-28","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":66},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT06982313","phase":"","title":"Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms","status":"COMPLETED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"1996-07-01","conditions":"Breast Cancer Invasive","enrollment":1545},{"nctId":"NCT06671912","phase":"PHASE3","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-19","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1156},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT01196936","phase":"PHASE2","title":"Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2010-09","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT06364267","phase":"PHASE2","title":"Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.","status":"RECRUITING","sponsor":"Andrea DeCensi","startDate":"2025-10-01","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT06033092","phase":"PHASE2","title":"Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Institute of Oncology","startDate":"2024-06-21","conditions":"BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ","enrollment":200},{"nctId":"NCT03346200","phase":"PHASE2","title":"Low Dose Tamoxifen for Mammographic Density Reduction","status":"COMPLETED","sponsor":"Per Hall","startDate":"2016-11","conditions":"Risk Reduction, Mammographic Density Reduction","enrollment":1440},{"nctId":"NCT04079517","phase":"PHASE1, PHASE2","title":"Karolinska Interventional Study of Mammograhic Density (Karisma-1)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-03","conditions":"Breast Cancer, Mammographic Density","enrollment":42},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":"Metastatic Breast Cancer, Tumor, Muscle Neoplasms","enrollment":100},{"nctId":"NCT01357772","phase":"PHASE3","title":"Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrea DeCensi","startDate":"2008-11-12","conditions":"Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms","enrollment":500},{"nctId":"NCT01579734","phase":"PHASE3","title":"Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2002-03","conditions":"Breast Cancer","enrollment":1884},{"nctId":"NCT04433494","phase":"PHASE1","title":"A Study of TY-302 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"TYK Medicines, Inc","startDate":"2020-12-07","conditions":"Breast Cancer, Solid Tumor","enrollment":60},{"nctId":"NCT04312347","phase":"NA","title":"Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels","status":"COMPLETED","sponsor":"Nalagenetics Pte Ltd","startDate":"2019-09-06","conditions":"ER+ Breast Cancer","enrollment":151},{"nctId":"NCT02603679","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-02","conditions":"Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor","enrollment":181},{"nctId":"NCT02197897","phase":"PHASE2","title":"Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2015-04-01","conditions":"Bladder Cancer","enrollment":15},{"nctId":"NCT04046159","phase":"PHASE3","title":"Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-04-30","conditions":"Breast Ductal Carcinoma in Situ","enrollment":810},{"nctId":"NCT02979301","phase":"NA","title":"Impact of Low-dose Tamoxifen on BPU","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-03-01","conditions":"High Background Uptake on MBI","enrollment":22},{"nctId":"NCT03147196","phase":"PHASE2","title":"Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2017-06-27","conditions":"Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma","enrollment":""},{"nctId":"NCT00723398","phase":"NA","title":"Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-03","conditions":"Breast Cancer","enrollment":266},{"nctId":"NCT00003199","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1997-11","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer","enrollment":50},{"nctId":"NCT00310531","phase":"PHASE3","title":"3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-02","conditions":"Osteopenia","enrollment":500},{"nctId":"NCT00002755","phase":"PHASE3","title":"Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Scottish Cancer Therapy Network","startDate":"1995-11","conditions":"Breast Cancer","enrollment":600},{"nctId":"NCT01075802","phase":"NA","title":"Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms","status":"COMPLETED","sponsor":"Western Sydney Local Health District","startDate":"2010-03","conditions":"Breast Cancer, CYP2D6 Polymorphism","enrollment":121},{"nctId":"NCT00002784","phase":"PHASE3","title":"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"1996-06","conditions":"Breast Cancer","enrollment":344},{"nctId":"NCT00431444","phase":"PHASE4","title":"Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Osteoporosis","enrollment":110},{"nctId":"NCT00749138","phase":"PHASE1","title":"Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy","status":"COMPLETED","sponsor":"Bader, Ted, M.D.","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":105,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LDT"],"phase":"phase_3","status":"active","brandName":"Low-dose tamoxifen","genericName":"Low-dose tamoxifen","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose tamoxifen acts as a selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while potentially having immunomodulatory effects at reduced doses. Used for Hormone receptor-positive breast cancer (investigational low-dose formulation), Potential immunomodulatory applications (Phase 3 investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}